Lincoln Pharma gets green signal from Australian regulator to enter the market

The approval is expected to add access to 30 more countries for exports

Lincoln Pharmaceuticals, a small-cap leading company of Gujarat, can now enter the Australian markets with approval from the Therapeutic Goods Administration (TGA) regulator of Australia. All three departments: capsule, tablets, and cream & ointment, have been approved. The company is focused on increasing its exports by expanding its reach. With this approval, it now has access to 90 plus countries. The exports sales contribution to revenues stood at 65 per cent in FY21 against 11 per cent in FY11, which reflects its focus on exports. 

In May 2020, it had received approval from EU GMP, to market its products across EU countries. The management believes that these approvals were steppingstones for it to expand its presence in regulated markets. 

Lincoln Pharmaceuticals Ltd manufactures affordable and innovative medicines in anti-bacterial, anti-infective, respiratory, cardio, gynaecology and various other segments. It has developed over 600 formulations in 15 therapeutic areas. 

The stock has a 52-week high and low of Rs 414.75 and Rs 191.40 respectively. Today at 1:05 pm, it was trading at Rs 392.5, down by 2 per cent on BSE.